Menopause Legislation in the United States: What Organizations Need to Know in 2026
In this post
Workplace laws — what passed
What the research confirms
What changed at the FDA
What this means for your org
Ready to build that strategy?
Menopause Policy and Research · Q1 2026 Update
This has never happened before.
Since January 1st, 2026, sixteen bills focused on menopause in the workplace have been introduced across the United States. One is already signed into law. The FDA removed a warning that shaped clinical decisions for twenty-two years. And two landmark studies confirmed what menopausal women have been reporting for years and what too many organizations have been slow to act on.
This is not a trend. This is a shift. And organizations that are not already having this conversation are about to have it forced on them.
Here is everything that changed in Q1 2026, and what it means for your practice, your workforce, and your patients.
16
Menopause bills introduced Q1 2026
1
Already signed into law
5
States with significant moves
Sixteen menopause bills in a single quarter. One is already law. The organizations leading on this are not waiting to be legislated into action. They are building the strategy now.
Menopause Workplace Laws: What Passed and What Is Moving
Five states made significant legislative moves between January and March 2026. The pace is unlike anything this space has seen before.
✅ Already Law
New Jersey — Menopause Coverage Act
Signed into law in January 2026. Insurers are now required to cover hormonal and non-hormonal therapies, pelvic floor physical therapy, bone health screenings, behavioral health care, and cardiovascular preventative services. This is not a proposal. It is in effect now.
⏳ Awaiting Governor
Virginia — Anti-Discrimination and Coverage
Two bills introduced: anti-discrimination protections for menopausal workers, and insurance coverage mandates for state-regulated health plans. Both were awaiting the governor’s signature at the close of Q1.
⏳ Introduced
New York — Accommodations and Paid Leave
Legislation banning job bias and requiring workplace accommodations for menopausal employees. A second bill mandates five paid days off per year for menopause-related symptoms. If passed, New York employers will have legal obligations they do not currently have.
🤝 Bipartisan
Michigan — Four Bipartisan Bills
Four bipartisan bills expanding menopause training, treatment coverage, and insurance access. The bipartisan support matters. This is not a single-party issue. It is a workforce issue.
💰 $3M Investment
California — Statewide Awareness Campaign
Governor Newsom proposed a $3 million statewide menopause awareness campaign and expanded coverage through the state budget, following his veto of two prior menopause bills. The direction of travel is clear even where individual bills have not yet passed.
“Rhode Island is currently the only state with explicit menopause workplace protections in effect. By the end of 2026, that number will be higher. The question is whether your organization is ahead of this or behind it.”
What the Research Is Now Confirming
Legislation does not move in a vacuum. It moves because the evidence is accumulating. Two significant studies published in Q1 2026 added weight to what menopausal women have been reporting for years.
40%
JAMA Cardiology · Q1 2026
Menopause and Cardiovascular Risk. Menopause before age 40 is associated with a 40% higher lifetime risk of coronary heart disease. The same study found that Black women are three times more likely to experience premature menopause. This is a clinical issue and a health equity issue at the same time.
🧠
Cambridge University · Q1 2026
Menopause and Brain Health. Researchers linked menopause to structural changes in the brain affecting memory and emotional regulation. For employers, this explains productivity and performance impacts that have gone unnamed and unaddressed.
The research is not new to the women living it. What is new is the clinical and legislative weight now behind it. That changes what organizations can reasonably claim they did not know.
What Changed at the FDA and Why It Matters
Q1 2026 brought three FDA developments with direct clinical implications.
❌
The Black Box Warning on HRT Is Gone
The FDA removed its black box warning on hormone replacement therapy in early 2026. That warning had been in place for twenty-two years, based on findings from the Women’s Health Initiative study that have since been significantly recontextualized by updated long-term evidence. In February 2026, the FDA approved updated labels for six specific HRT products including Prometrium, Divigel, and Bijuva. Risk statements about cardiovascular disease, breast cancer, and probable dementia were formally removed. Many patients were denied HRT or declined it based on that warning. That calculus has now changed, and your patients will be asking about it.
⚠️
Estrogen Patch Shortages
Demand for HRT has surged following the label changes. Estrogen patch shortages are now being reported at pharmacies nationwide. Patients seeking HRT may face availability challenges, and practices should anticipate an increase in questions about alternatives.
✅
Two New Approved Treatments Now Available
Addyi was approved for low sexual desire in postmenopausal women and is now available for purchase. Lynkuet, a non-hormonal daily pill approved for moderate to severe hot flashes, is also now available. Both expand the treatment options your patients can ask about.
What This Means for Your Organization
The menopause conversation is no longer something organizations can defer. Legislation is moving in multiple states. Research is confirming systemic health impacts. The FDA has revised its clinical guidance. And the women in your waiting rooms and your workforce are paying closer attention than ever before.
The organizations that will lead on this are not waiting to be legislated into action. They are building the education, the policy, and the support infrastructure now — before the law requires it and while it still signals genuine commitment rather than legal compliance.
The question is not whether menopause affects your organization. It does. The question is whether your organization is equipped to respond with the right education, the right clinical knowledge, and the right strategy.
If your organization has not started talking about menopause, legislation is about to make that conversation unavoidable. The organizations that lead will not be the ones who waited..
Ready to Build That Strategy?
I track these developments so your team does not have to. Whether you are a healthcare provider looking to better support menopausal patients, or an organizational leader building a workforce menopause strategy, this is exactly what I do.
Healthcare Providers
Learn About the Menopause Care Partner Model
Better outcomes for your patients. A practice that leads on menopause care. Let’s talk about what that looks like for your specific context.
HR Directors and Organizations
Menopause Workplace Workshops
Your workforce does not leave their hormones at the door. Build the strategy before the law requires it — and before your competitors do.
For Organizations
Menopause Workplace Workshops
Build the strategy before the law requires it. Workshops from $299 for HR teams and leadership.
From LaVaughn
I Got You.
The shift is already happening. The question is whether your organization will lead it
Ready To Work Together?
